Scholarlink

<p>Schimmelpenning-Feuerstein-Mims syndrome (SFMS) is a rare mosaic RASopathy associated with epidermal nevi, neurological abnormalities, and increased cancer risk. We report a 2-year-old girl with <i>HRAS</i>-related SFMS, aggressive orbital rhabdomyosarcoma (eRMS) and severe hypophosphatemic rickets resistant to standard therapies. Treatment with the MEK inhibitor trametinib improved phosphate regulation, reducing FGF23 levels, and led to rapid developmental progress, including independent walking. After 29 months, the patient remains in cancer remission with stable phosphate levels. This case highlights trametinib’s potential in managing complex manifestations in SFMS and suggests MEK inhibitors as promising for treating mosaic RASopathies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Targeted treatment of hypophosphatemia with trametinib in HRAS-related mosaic RASopathy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月3日

查看全文
  • Adil Mirza,
  • Corinne Rossi,
  • Andreas Kulozik,
  • Rouzbeh Banan,
  • Felix Sahm,
  • Semi Harrabi,
  • Steffen Syrbe,
  • Daniela Choukair

摘要

Schimmelpenning-Feuerstein-Mims syndrome (SFMS) is a rare mosaic RASopathy associated with epidermal nevi, neurological abnormalities, and increased cancer risk. We report a 2-year-old girl with HRAS-related SFMS, aggressive orbital rhabdomyosarcoma (eRMS) and severe hypophosphatemic rickets resistant to standard therapies. Treatment with the MEK inhibitor trametinib improved phosphate regulation, reducing FGF23 levels, and led to rapid developmental progress, including independent walking. After 29 months, the patient remains in cancer remission with stable phosphate levels. This case highlights trametinib’s potential in managing complex manifestations in SFMS and suggests MEK inhibitors as promising for treating mosaic RASopathies.